Complex Insight - Understanding our world

The Pharmaceutical industry continues to adopt simulation technologies for drug discovery and development. This week Simulations Plus, Inc., a provider of simulation and modeling software announced it had signed a collaboration agreement with a major pharmaceutical company to add a transdermal and subcutaneous dosing model within its GastroPlus simulation software program. GastroPlus™ is a mechanistic, physiologically-based simulation program that predicts the absorption, pharmacokinetics, and pharmacodynamics for drugs given through oral, intravenous, ocular or pulmonary routes.The funded collaboration enable Simulations Plus to extend the competitive advantage of GastroPlus without the need for Simulations Plus to fund the development directly.